Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B

Table 1 Effects of rhGH on liver function of patients with severe chronic hepatitis B (mean±SD).

Marker of liver function	Pretreatment n = 28	2-wk treatment n = 28	4-wk treatment n = 16
Total protein (g/L)	51.6±4.3	67.8±8.4a	69.2±7.8
Prealbumin (g/L)	80±28	107±54a	108±55
Albumin (g/L)	26.1±4.1	30.2±5.3a	31.9±5.1b
Cholesterol (mg/dL)	76±17	86±32a	96±39
Total bilirubin (mg/dL)	15±14	20±16	12±13
PTA (%)	21.3±5.5	24.7±12.2	36.8±7.9
ALT (IU/L)	117±210	83±77	59±43
AST (IU/L)	171±243	104±79	76±56

^aP<0.05,

^bP<0.01 vs pretreatment.

Table 2 Effects of rhGH on GH-IGF axis in patients with severe chronic hepatitis B (mean±SD).

Marker of GH-IGF axis	Pretreatment (n = 15)	2-wk treatment (n = 15)
GH (ng/mL)	10.4±7.6	6.2±8.1a
IGF-1 (mg/mL)	6.3±4.5	8.8±6.7
IGFBP1 (ng/mL)	56.8±47.2	89.7±50.3a
IGFBP3 (mg/mL)	3.5±1.7	5.1±3.4

^aP<0.05 vs pretreatment.